



[54] METHOD OF USING CROSSLINKED POLYMER COMPOSITIONS IN TISSUE TREATMENT APPLICATIONS

[75] Inventors: Woonza M. Rhee, Palo Alto; Frank A. DeLustro, Belmont; Richard A. Berg, Los Altos, all of Calif.

[73] Assignee: Cohesion Technologies, Inc., Palo Alto, Calif.

[21] Appl. No.: 09/302,852

[22] Filed: Apr. 30, 1999

Related U.S. Application Data

[63] Continuation of application No. 09/229,851, Jan. 13, 1999, Pat. No. 6,051,648, which is a continuation of application No. 08/769,806, Dec. 18, 1996, Pat. No. 5,874,500, which is a continuation-in-part of application No. 08/573,799, Dec. 18, 1995, abandoned.

[51] Int. Cl. 7 ..... C08F 283/00; C08G 63/91; C08G 63/48

[52] U.S. Cl. .... 525/54.1; 525/419; 525/420; 525/425

[58] Field of Search ..... 525/54.1, 419, 525/420, 425

[56] References Cited

U.S. PATENT DOCUMENTS

3,619,371 11/1971 Crook et al. .
3,742,955 7/1973 Battista et al. .
3,788,948 1/1974 Kegadal et al. .
3,810,473 5/1974 Cruz, Jr. et al. .
3,876,501 4/1975 Hanushewsky .
3,949,073 4/1976 Daniels et al. .
3,960,830 6/1976 Bayer et al. .
4,002,531 1/1977 Royer .
4,055,635 10/1977 Green et al. .
4,088,538 5/1978 Schneider .
4,101,380 7/1978 Rubinstein et al. .
4,164,559 8/1979 Miyata et al. .
4,179,337 12/1979 Davis et al. .
4,192,021 3/1980 Deibig et al. .
4,238,480 12/1980 Sawyer .
4,261,973 4/1981 Lee et al. .
4,279,812 7/1981 Cioca .
4,301,144 11/1981 Iwashita et al. .
4,314,380 2/1982 Miyata .
4,320,201 3/1982 Berg et al. .
4,357,274 11/1982 Werner .
4,390,519 6/1983 Sawyer .
4,404,970 9/1983 Sawyer .
4,412,947 11/1983 Cioca .
4,412,989 11/1983 Iwashita .
4,414,147 11/1983 Klibanov et al. .
4,415,628 11/1983 Cioca et al. .
4,415,665 11/1983 Mosbach et al. .
4,424,208 1/1984 Wallace et al. .
4,451,568 5/1984 Sneider et al. .
4,488,911 12/1984 Luck et al. .
4,495,285 1/1985 Shimizu et al. .
4,496,689 1/1985 Mitra .
4,515,637 5/1985 Cioca .
4,544,516 10/1985 Hughes et al. .

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

2134744 5/1995 Canada .
0013249 1/1980 European Pat. Off. .
0042253 12/1981 European Pat. Off. .
0154447 9/1985 European Pat. Off. .
0157359 10/1985 European Pat. Off. .
0171176 2/1986 European Pat. Off. .
0243179 10/1987 European Pat. Off. .
0330389 8/1989 European Pat. Off. .
0341007 11/1989 European Pat. Off. .
0431479A1 6/1991 European Pat. Off. .
0466383 1/1992 European Pat. Off. .
0575273 12/1993 European Pat. Off. .
0640647 3/1995 European Pat. Off. .
0656214 6/1995 European Pat. Off. .
0656215 6/1995 European Pat. Off. .
0680990 11/1995 European Pat. Off. .
0732109 9/1996 European Pat. Off. .
2628634 9/1989 France .
4-227265 4/1990 Japan .
60-70972 3/1994 Japan .
WO 84/01106 3/1984 WIPO .
WO 85/04412 10/1985 WIPO .
WO 87/04078 7/1987 WIPO .
WO 90/05755 5/1990 WIPO .
WO 92/13025 8/1992 WIPO .
WO 92/13578 8/1992 WIPO .
WO 94/01483 1/1994 WIPO .
WO 94/03155 2/1994 WIPO .

OTHER PUBLICATIONS

Harris, J. Milton, Ed., Poly(ethylene Glycol) Chemistry: Biotechnical & Biomedical Applications, Chapter 22, Plenum Press, NY (1992).
Dewent abstract of Japanese Patent Publication No. 07-090241 (Apr. 4, 1995).
West et al., "Comparison of covalently and physically cross-linked polyethylene glycol-based hydrogels for the prevention of postoperative adhesions in a rat model", Biomaterials (1995) 16:1153-1156.

(List continued on next page.)

Primary Examiner—Nathan M. Nutter
Attorney, Agent, or Firm—Morrison & Foester, LLP

[57] ABSTRACT

Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.